Tenatumomab  (Synonyms: ST2146)

Tenatumomab (ST2146) is a murine monoclonal antibody against tenascin-C. And tenascin-C, the large extracellular glycoprotein, is overexpressed in cancer. Tenatumomab has been used for Pretargeted Antibody Guided Radioimmunoresearch (PAGRIT), and delivering radionuclides to tumors via PAGRIT and direct 131Iodine labeling approach^[1][2].

tenascin-C^[1][2]

Tenascin-C is a hexameric glycoprotein found in the extracellular matrix of embryos and adults. It has preferential expression in malignant solid tumors and hematologic tumors. Tenascin-C is spatially and temporally associated with tumor neovasculars and may exert anti-adhesion and immunosuppressive activities^[2].
Tenatumomab (2-5 μg/mL; 16 h) retains immunoreactivity upon biotinylation. And Tenatumomab can be conjugated to up to 20 biotins per mAb,maintaining >50% immunoreactivity^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Tenatumomab (4 μg/mouse; i.v.; single dose) shows a biodistribution associated with low and high tenascin expression in nude mice transplanted with human HT-29 colon carcinoma and/or human U-118MG glioblastoma cells, respectively^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1412891-40-7

Liquid

Colorless to light yellow

[Tenatumomab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Giannini G, et al. Synthesis and preliminary in vitro evaluation of DOTA-Tenatumomab conjugates for theranostic applications in tenascin expressing tumors. Bioorg Med Chem. 2019 Aug 1;27(15):3248-3253.  [Content Brief]

  [2]. De Santis R, et al. Low and high tenascin-expressing tumors are efficiently targeted by ST2146 monoclonal antibody. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2191-6.  [Content Brief]